| scholarly article | Q13442814 |
| P2093 | author name string | David A Weinstein | |
| Bryon E Petersen | |||
| Thomas D Shupe | |||
| Dana G Pintilie | |||
| Max Salganik | |||
| Susan V Salganik | |||
| P2860 | cites work | Mutations in the glucose-6-phosphatase gene that cause glycogen storage disease type 1a | Q24317268 |
| Correction of glycogen storage disease type 1a in a mouse model by gene therapy | Q28508399 | ||
| A potential new role for muscle in blood glucose homeostasis | Q28508734 | ||
| Isolation of the gene for murine glucose-6-phosphatase, the enzyme deficient in glycogen storage disease type 1A | Q28594080 | ||
| Functional integration of hepatocytes derived from human mesenchymal stem cells into mouse livers. | Q30319983 | ||
| Identification and characterization of a human cDNA and gene encoding a ubiquitously expressed glucose-6-phosphatase catalytic subunit-related protein | Q34153492 | ||
| Mutations in the glucose-6-phosphatase gene are associated with glycogen storage disease types 1a and 1aSP but not 1b and 1c | Q34194712 | ||
| Historical highlights and unsolved problems in glycogen storage disease type 1. | Q34954560 | ||
| Adenovirus-mediated gene therapy in a mouse model of glycogen storage disease type 1a. | Q34954613 | ||
| Glycogen storage diseases | Q35078487 | ||
| Impaired neutrophil activity and increased susceptibility to bacterial infection in mice lacking glucose-6-phosphatase-beta | Q35635511 | ||
| Liver transplantation in children with glycogen storage disease: controversies and evaluation of the risk/benefit of this procedure | Q37097027 | ||
| Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer | Q40384759 | ||
| Generation of human artificial chromosomes expressing naturally controlled guanosine triphosphate cyclohydrolase I gene | Q40700937 | ||
| Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature | Q41460619 | ||
| Delivery of glucose-6-phosphatase in a canine model for glycogen storage disease, type Ia, with adeno-associated virus (AAV) vectors | Q44052705 | ||
| Sustained hepatic and renal glucose-6-phosphatase expression corrects glycogen storage disease type Ia in mice | Q44110024 | ||
| A glucose-6-phosphate hydrolase, widely expressed outside the liver, can explain age-dependent resolution of hypoglycemia in glycogen storage disease type Ia. | Q44586480 | ||
| Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia. | Q45417049 | ||
| AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. | Q45876170 | ||
| Ontogeny of the murine glucose-6-phosphatase system. | Q52184202 | ||
| Management of hepatic adenoma in glycogen storage disease Ia | Q72151182 | ||
| Magnetic resonance imaging findings of hepatic adenomas in von Gierke (type I) glycogen storage disease: case report | Q77999721 | ||
| P433 | issue | 9 | |
| P921 | main subject | glycogen storage disease | Q1421738 |
| P304 | page(s) | 1032-1042 | |
| P577 | publication date | 2009-07-06 | |
| P1433 | published in | Laboratory Investigation | Q6467260 |
| P1476 | title | A detailed characterization of the adult mouse model of glycogen storage disease Ia. | |
| P478 | volume | 89 |
| Q42681991 | Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis |
| Q38244085 | Lessons from new mouse models of glycogen storage disease type 1a in relation to the time course and organ specificity of the disease |
| Q26860745 | Metabolic reprogramming by class I and II histone deacetylases |
| Q39689270 | Neonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus-based vector |
| Q92345005 | Pathogenesis of Hepatic Tumors following Gene Therapy in Murine and Canine Models of Glycogen Storage Disease |
Search more.